Enanta announced that its oral RSV candidate zelicapavir has been accepted for two oral presentations at ESCMID Global 2026, a leading infectious‑disease forum that will run from April 17‑21 in Munich, Germany. The presentations are scheduled for April 18 and will provide the scientific community with detailed efficacy and safety data from the company’s recent Phase 2b studies.
The acceptance follows positive topline data from the Phase 2b RSVHR study in high‑risk adults, which was announced on September 29 2025. While the primary endpoint for time to resolution of lower‑respiratory‑tract‑disease symptoms was missed, the study demonstrated clinically meaningful improvements in secondary endpoints and in a high‑risk subgroup. A Phase 2 study in pediatric patients, announced in December 2024, also showed encouraging results, underscoring the breadth of the program’s potential.
Zelicapavir is an oral N‑protein inhibitor that has received Fast‑Track designation from the U.S. Food and Drug Administration. The company estimates a $1 billion market for an oral RSV antiviral, reflecting the unmet need for effective, easy‑to‑administer treatments in high‑risk adults and children.
The conference presentations will detail key metrics such as time to symptom resolution, viral‑load reduction, and hospitalization rates, providing external validation that will support the design of a Phase 3 program and potential FDA submission.
Management highlighted the significance of the data: “We are highly encouraged by these results from our Phase 2b trial of zelicapavir in high‑risk adults infected with RSV. These data demonstrate the potential for zelicapavir to reduce the duration of RSV symptoms in high‑risk adults who face an increased risk of hospitalization or death from this virus,” said Dr. Scott T. Rottinghaus, Chief Medical Officer. CEO Jay R. Luly added, “Building on the progress we achieved in our RSV and immunology portfolios this past year, we enter 2026 with strong momentum as we continue to expand our pipeline and deliver on key milestones.”
The milestone marks a tangible step toward Enanta’s transition from a royalty‑collecting company to an active drug developer, reinforcing the company’s strategic shift and strengthening its potential revenue streams from the RSV program.
The RSV market remains crowded with prophylactic options such as monoclonal antibodies, but an oral antiviral remains a critical unmet need. Zelicapavir’s unique mechanism and favorable safety profile position it to fill this gap and compete effectively in the evolving therapeutic landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.